Skip to main content
. Author manuscript; available in PMC: 2016 Mar 1.
Published in final edited form as: Br J Dermatol. 2015 Feb 5;172(3):760–768. doi: 10.1111/bjd.13350

Figure 2.

Figure 2

Figure 2

IgG anti – desmoglein 1(A) and anti –desmoglein 3 (B) values. Median IgG anti- DSG1 (A) levels in the per-protocol population were lower in subjects treated with infliximab (N = 6) when compared to subjects treated with placebo (N=7) (week 0 = NS; week 26, p = 0.022). Median IgG anti DSG3 (B) levels were also lower at week 0 and week 26 in infliximab treated subjects (week 0 = NS; Week 26 p = 0.051).